Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SonarMD

Explore full profile

Provides care management for complex chronic conditions that use high-cost drugs

Chicago, United StatesFounded 2015Biotech & Life Sciences
Valuation $50–100M Last recorded · 2023
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for SonarMD and the history behind them.

About SonarMD

SonarMD operates as a specialized care coordination company focused on the digestive health market, particularly for patients with chronic conditions like Inflammatory Bowel Disease (IBD), which includes Crohn's disease and ulcerative colitis. The company was founded in 2015 by Dr. Lawrence R. Kosinski, a gastroenterologist with over three decades of clinical experience. His journey to creating SonarMD stemmed from his work building the Illinois Gastroenterology Group into the state's largest practice and a desire to shift gastroenterology from a fee-for-service model to a value-based care framework. This mission was catalyzed by a successful project with Blue Cross Blue Shield of Illinois to reduce costs and complications for Crohn's disease patients.

The firm's business model is rooted in value-based arrangements with health plans (payers) and gastroenterology practices (providers). SonarMD contracts with payers to manage their high-risk IBD patient populations, generating revenue by sharing in the cost savings realized from reduced healthcare utilization, such as emergency room visits and hospitalizations. This model aligns financial incentives, allowing providers to earn a share of the savings for their role in coordinating care, without altering their standard fee-for-service reimbursements. The service is typically provided at no cost to the enrolled patients or the participating medical practices.

The core of SonarMD's offering is a digital health platform that facilitates continuous patient monitoring between office visits. Patients participate by responding to monthly health assessments delivered via text or email, which are based on validated clinical surveys. A proprietary algorithm then analyzes these patient-reported outcomes to generate a numerical "Sonar Score," which tracks the patient's health status over time. The platform uses predictive analytics to identify patients at risk of clinical deterioration. When the system flags a concerning trend, SonarMD's clinical care team intervenes by contacting the patient for more details and then alerting the patient's specialist practice to enable early and proactive treatment before a health crisis occurs. To provide comprehensive support, the company also partners with other services to offer patients access to nutrition counseling, mental health services, and sleep improvement programs.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
Chicago, United States
Employees
23
Open positions
None listed
Dealroom signal
73.2/100
Industry
Health
Sub-industry
Pharmaceutical, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Jul 2024 $1M $4M Undisclosed ↗
EARLY VC✓Equity / VC May 2023 $4.3M $50M Undisclosed ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

SonarMD website traffic

Latest recorded traffic for SonarMD is 1.4K monthly website visits, down 36.4% over the last three months. SonarMD's team grew 15% over the past year.

Latest monthly visits1.4K 3-month web change-36.4% 1-year team growth+15%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Arboretum Ventures
  • Blue Venture Fund
  • Blue Cross and Blue Shield Association

Other known investors4 additional known investors

  • K50 Ventures
  • KohFounders
  • Nueterra Capital
  • Tensility Venture Partners
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States95%
🇧🇷 Brazil5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SonarMD on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SonarMD’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.